Altimmune clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164PemvidutideRecruiting2028-12Estimated

Phase 2 6 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24. After: Measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 121 participants (actual).

Primary completion date changed

Before: 31 Mar 2027. After: 30 Sep 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method. After: Measure: Change from baseline in the average number of heavy drinking days per week.

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: May 2026. After: 30 Jul 2026.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis). After: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) Measure: Incidence of Treatment Emergent Adverse Events.

Primary completion date changed

Before: 29 Apr 2025. After: 25 Nov 2025.

Check registry source

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 190 participants (planned). After: 212 participants (actual).

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source